Uy Ear
Stock Analyst at Mizuho
(3.94)
# 635
Out of 5,043 analysts
70
Total ratings
48.78%
Success rate
13.71%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $29.72 | +51.41% | 6 | Oct 27, 2025 | |
| QURE uniQure | Maintains: Outperform | $30 → $60 | $67.92 | -11.66% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $17.44 | +221.10% | 2 | Sep 24, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $24 | $22.99 | +4.39% | 14 | Aug 7, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $40 → $14 | $23.50 | -40.43% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $18.62 | +356.50% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $19.64 | +6.92% | 14 | Feb 26, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $2.33 | -57.08% | 1 | Dec 5, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $8.85 | +351.98% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $7.22 | +218.56% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $148.94 | -6.00% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $190.30 | -78.98% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.79 | +258.42% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.56 | +92.31% | 2 | Mar 1, 2023 |
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $29.72
Upside: +51.41%
uniQure
Sep 25, 2025
Maintains: Outperform
Price Target: $30 → $60
Current: $67.92
Upside: -11.66%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $17.44
Upside: +221.10%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $22.99
Upside: +4.39%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $40 → $14
Current: $23.50
Upside: -40.43%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $18.62
Upside: +356.50%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $19.64
Upside: +6.92%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $2.33
Upside: -57.08%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $8.85
Upside: +351.98%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $7.22
Upside: +218.56%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $148.94
Upside: -6.00%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $190.30
Upside: -78.98%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.79
Upside: +258.42%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.56
Upside: +92.31%